Last reviewed · How we verify

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Efsubaglutide Alfa Injection Efsubaglutide Alfa Injection marketed

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-yinnuo-pharmaceutical-technology-co-ltd. Accessed 2026-05-16.

Related